Cirina Hong Kong

Cirina Hong Kong is rated 3 out of 5 in the category biotechnology. Read and write reviews about Cirina Hong Kong. Cirina is a privately held company focused on the early detection of cancer. Cirina is developing innovative blood-plasma tests to detect deadly diseases at their earliest stages when curative treatments are most viable. The company was co-founded by world renowned scientist in non-invasive molecular diagnostics, Prof. Dennis Lo, his colleagues Prof. Rossa Chiu and Prof. Allen Chan at the Chinese University of Hong Kong (CUHK), and lead investor, Decheng Capital. The company is headquartered in Hong Kong with research and development teams in Hong Kong and South San Francisco. GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, announced on 31 May 2017 that it has entered into a definitive agreement to combine with Cirina, Ltd.. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company’s funding was led by ARCH Venture Partners and includes Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent, Varian Medical Systems, and other financial partners.